SCHEMBL2035642

SCHEMBL2035642

[c]1ccccc1Cc1ncc[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 11/20 0.56
ADRA2A P08913 1/20 0.46
ADRA2B P18089 1/20 0.46
ADRA2C P18825 1/20 0.46
HTR1A P08908 1/20 0.45
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
GLA P06280 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
GAA P10253 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359245 0.85 TAAR1 (0.46) TAAR1ADRA2AADRA2BADRA2CHTR1A
SCHEMBL5362548 0.82 TAAR1 (0.44) TAAR1ADRA2AADRA2BADRA2CHTR1A
SCHEMBL28103549 0.74 ADRA2A (0.69) TAAR1ADRA2AADRA2BADRA2CHTR1A
SCHEMBL5758315 0.73 TAAR1 (0.45) TAAR1ADRA2AADRA2BADRA2CHTR1A
SCHEMBL1679282 0.72 TAAR1 (0.64) TAAR1ADRA2AADRA2BADRA2CHTR1A
SCHEMBL15031 0.72 CALM1 (0.32)
SCHEMBL9243 0.72 TAAR1 (1.00) TAAR1ADRA2AADRA2BADRA2CHTR1A
Ammonia Solution, Strong SCHEMBL27639428 0.71 TAAR1 (0.96) TAAR1ADRA2AADRA2BADRA2CHTR1A
Hydrochloric Acid SCHEMBL27290500 0.71 TAAR1 (0.96) TAAR1ADRA2AADRA2BADRA2CHTR1A
Bromide SCHEMBL29135558 0.71 TAAR1 (0.96) TAAR1ADRA2AADRA2BADRA2CHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365557-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. (KR) 2023-11-16 US claimed
US-11802126-B2 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders 1ST Biotherapeutics, Inc. (KR) 2023-10-31 US claimed
EP-3692023-B1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST BIOTHERAPEUTICS INC (KR) 2023-05-17 EP claimed
EP-3927706-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF PROLIFERATIVE DISORDERS 1st Biotherapeutics, Inc. (KR) 2021-12-29 EP claimed
EP-3927705-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1st Biotherapeutics, Inc. (KR) 2021-12-29 EP claimed
US-20210353631-A1 1,4-Benzoxazines for the Treatment of Cancers and Other Neurodegenerative Diseases Neugeneron LLC 2021-11-18 US claimed
US-20210347774-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. 2021-11-11 US claimed
CN-113454081-A Imidazopyridinyl compounds and their use for the treatment of proliferative diseases 第一生物治疗股份有限公司 2021-09-28 CN claimed
CN-113454082-A Imidazopyridinyl compounds and their use for the treatment of neurodegenerative diseases 第一生物治疗股份有限公司 2021-09-28 CN claimed
US-10968188-B2 Benzothiazol compounds and methods using the same for treating neurodegenerative disorders 1ST Biotherapeutics, Inc. (KR) 2021-04-06 US claimed
WO-2019070093-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. (KR) 2019-04-11 WO claimed
US-20190100500-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. 2019-04-04 US claimed
US-20120094991-A1 1, 4-Benzoxazine Compounds and Derivatives Thereof as Therapeutic Drugs for the Treatment of Neurodegenerative Conditions Southerm Methodist University (US) 2012-04-19 US claimed
WO-2007135417-A1 BENZOTRIAZEPINONE DERIVATIVES JAMES BLACK FOUNDATION (GB) 2007-11-29 WO claimed
EP-0830349-B1 METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS DU PONT PHARM CO (US) 2000-03-22 EP claimed
US-5877312-A Method for preparing alkylating agents for their use for alkylating cyclic ureas DUPONT PHARMACEUTICALS COMPANY (US) 1999-03-02 US claimed
US-5756493-A ACTIVE AGAINST METHICILLIN RESISTANT BACTERIA MICROCIDE PHARMACEUTICALS, INC. (US) 1998-05-26 US claimed
US-5637780-A Method for preparing alkylating agents and their use for alkylating cyclic ureas THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-06-10 US claimed
WO-1996039393-A1 METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-12-12 WO claimed
WO-1996000708-A1 METHOD FOR PREPARING ALKYLATING AGENTS AND THEIR USE FOR ALKYLATING CYCLIC UREAS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-01-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365557-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SMN1; SMN2, SNCA, HTT TAAR1 3756/4885ADRA2A 1960/4885ADRA2B 1886/4885
US-20190100500-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS ABL2, ABL1, MAPT TAAR1 3579/4885ADRA2A 3693/4885ADRA2B 3099/4885
US-20210353631-A1 1,4-Benzoxazines for the Treatment of Cancers and Other Neurodegenerative Diseases GBA1, NFXL1, CYP4X1 TAAR1 2245/4885ADRA2A 1984/4885ADRA2B 2269/4885
US-20120094991-A1 1, 4-Benzoxazine Compounds and Derivatives Thereof as Therapeutic Drugs for the Treatment of Neurodegenerative Conditions HYPK, HTT, HIPK4 TAAR1 2784/4885ADRA2A 1107/4885ADRA2B 1060/4885
US-11802126-B2 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders SMN1; SMN2, SNCA, HTT TAAR1 3756/4885ADRA2A 1960/4885ADRA2B 1886/4885
US-10968188-B2 Benzothiazol compounds and methods using the same for treating neurodegenerative disorders ABL2, ABL1, MAPT TAAR1 3579/4885ADRA2A 3693/4885ADRA2B 3099/4885
US-20210347774-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SMN1; SMN2, SNCA, HTT TAAR1 3756/4885ADRA2A 1960/4885ADRA2B 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.